Inferra AI / Company / IOVA
Iovance Biotherapeutics, Inc.
IOVA · Health Care
Last earnings Aug 6, 2026
Key results
Revenuequarter
93%
Year-over-year product revenue increased by 93% compared to $31.1 million in the second quarter of 2024.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Product revenuequarter
$5.9 million
o 2Q25 Proleukin Revenue: Product revenue also included $5.9 million in Proleukin sales, reflecting restocking orders from two major U.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenue was $60.0 million for the second quarter of 2025, a 22% increase from $49.3 million in the first quarter of 2025 and a 93% increase over revenue of $31.1 million in the second quarter of 2024.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Product revenue was $54.1 million for Amtagvi and $5.9 million for Proleukin in the second quarter of 2025 compared to $12.8 million for Amtagvi and $18.3 million for Proleukin in the second quarter of 2024.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenue was $109.3 million for the first half of 2025, an increase of 243% over revenue of $31.8 million in the prior year six-month period.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Product revenue from Amtagvi and Proleukin was $97.7 million and $11.6 million, respectively, in the first half of 2025 compared to $12.8 million and $19.0 million, respectively, in the first half of 2024.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | 93% | — | — |
| Product revenue | $5.9 million | — | — |
Guidance · company-stated
Direction: Reiterated
“htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif.”
“· Full Year 2025 Total Product Revenue Guidance: Iovance is reiterating total product revenue guidance within the range of $250 to $300 million in the first full calendar year of Amtagvi sales.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Based on the funds the Company has available as of the date these condensed consolidated financial statements are issued, the Company believes that it has sufficient capital to fund its anticipated operating expenses and capital expenditures as planned for at least the next twelve months from the date these condensed consolidated financial statements are issued.
The cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity.
Event summary
Iovance Biotherapeutics, Inc. — Earnings release (2025-08-07)
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Reiterated
Revenue: “htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif.”
Revenue: “· Full Year 2025 Total Product Revenue Guidance: Iovance is reiterating total product revenue guidance within the range of $250 to $300 million in the first full calendar year of Amtagvi sales.”
Revenue — Reiterated (“Reiterated”)
“htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif.”
Revenue — Reiterated (“reiterating”)
“· Full Year 2025 Total Product Revenue Guidance: Iovance is reiterating total product revenue guidance within the range of $250 to $300 million in the first full calendar year of Amtagvi sales.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Based on the funds the Company has available as of the date these condensed consolidated financial statements are issued, the Company believes that it has sufficient capital to fund its anticipated operating expenses and capital expenditures as planned for at least the next twelve months from the date these condensed consolidated financial statements are issued.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
government agencies as well as corporate debt securities and commercial paper, and places restrictions on maturities and concentration by type and issuer, except for securities issued by the U.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
In determining the net present value of lease payments, the Company uses an estimated incremental borrowing rate that is applicable to the Company based on the information available at the later of the lease commencement or modification date.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The fair value of the Company's common stock option grants is estimated using a Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected term of the common stock options, and future dividends.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2025 financial results and corporate updates.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Launch Expansion into New Markets Amtagvi has the opportunity to address more than 30,000 patients globally with previously treated advanced melanoma.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
A new strategy is in development to make Amtagvi and TIL therapy broadly accessible to patients in the EU.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
o Australia’s Therapeutic Goods Administration granted Priority Review with a decision anticipated in early 2026.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Risks & headwinds
Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.
SEC original ↗Iovance Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Legal Proceedings 47 Item 1A.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
We caution you that the risks, uncertainties and other factors referenced above may not contain all the risks, uncertainties and other factors that are important to you.
SEC original ↗Iovance Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewIovance Biotherapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Iovance Biotherapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documentsEarnings releases
12 documentsPresentations
2 documents
Transcripts
0 documentsNo transcripts for Iovance Biotherapeutics, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.